Lobular Breast Cancer Alliance Inc

What it reported doing in 2024

During the last fiscal year, lbca:-launched first october 15th global lobular breast cancer awareness day in collaboration with advocates and researchers around the world and worked with a pr company to raise awareness of ilc and lbca in several key metropolitan areas around the us. Worked with three major cancer centers (dana farber, memorial sloan kettering and md anderson) to encourage their implementing oct 15th ilc awareness raising events and launching their own ilc programs-supported two and launched a third local advocacy team (lat) in cascadia (Oregon and Washington state region) to increase lbca's work with advocates conducting education and research advocacy in their communities (cont'd in schedule o) -created ilc info graphics for centers for disease control and prevention (cdc) and for national cancer institute (nci) breast cancer patient facing pages -produced text for report on ilc and nci seer ilc incidence data that was published on the nci cancer stat facts webpage and will be updated annually.-produced patient resource document on lobular breast cancer myths and facts-funded ilc research grants with society of nuclear medicine and molecular imaging (snmmi), asco / conquer cancer foundation, and american association for cancer research. Funded/issued in collaboration with susan g. Komen first ever metastatic ilc research grant solicitation in memory of lbca founding advocate julia k. Levine-helped australia lobular breast cancer patients form lbca-aus for patient advocacy and helped brazilian clinicians develop training curriculum on ilc for mds.-supported launch of two virtual support groups for individuals with metastatic ilc-co-sponsored and presented poster on lbca's october 15th movement at ilc symposium in leuven, belgium in september 2024-produced and presented poster on ilc patient experience with surgical treatment planning in december at san antonio breast cancer symposium 24-developed and shared on website and social media lay summaries of all ilc posters presented at sabcs 24, to make the research presented accessible to lay audiences-initiated, funded and awarded merit scholarships (to cover conference attendance travel costs) for top five best ilc research posters presented at sabcs24 via administrative partnership with aacr. Developed and shared on website/newsletter, lay summaries of 25 ilc research posters presented at sabcs including merit winners.-managed website with (ever-increasing hits) that provides detailed information for the public about invasive lobular breast cancer (ilc), ilc research, clinical trials and patient advocacy opportunities. -hosted 4 webinars for ilc patient advocates on research and other topics, and provided 17 travel scholarships to patient advocates to attend trainings and conferences-released 2 ilc curriculums for clinicians available for viewing as webinars for cmes on memorial sloan kettering (msk) cancer center educational portal-sponsored scientific advisory board meetings to involve ilc researchers in advocacy and in the development of the information lbca disseminates-sponsored patient advocate advisory board meetings to involve ilc patient advocates in ilc awareness raising activities and strategic planning-published monthly newsletter reaching over 7,200 subscribers-added 60+ new ilc studies to the julia k. Levine ilc publications library on the lbca website

Financial Efficiency

• Mission deployment rate: 49.9%; rating input score 50
• Program expense ratio: 75.3%; rating input score 75
• Fundraising efficiency: $11.08 raised per $1 spent on fundraising; rating input score 41; 41st percentile among comparable filings

Transparency & Controls

• Consistency checks: 92.9%; rating input score 93; 19th percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: 0 of 8 controls in place; rating input score 0
  • Claims monitoring procedures: Limited
  • Requires narrative reports: Limited
  • Conducts field audits: Limited
  • May suspend future funding: Limited
  • Requires financial reports: Limited
  • Conducts site visits: Limited
  • Requires grant agreements: Limited
  • May require repayment: Limited
• Grant itemization coverage: 99.6%; rating input score 100; 50th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 87.5%; rating input score 88; 21st percentile among comparable filings
• Governance controls: 7 of 8 controls in place; rating input score 88
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Fail
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 35.1%; rating input score 87; 87th percentile among comparable filings
• Total-asset coverage ratio: 1.24; rating input score 50; 50th percentile among comparable filings
• Liabilities to assets ratio: 0.02; rating input score 62; 62nd percentile among comparable filings
• Officer compensation ratio: 18.8%; rating input score 16; 16th percentile among comparable filings

Growth

• Program expense growth: 29.8% per year; rating input score 100; 90th percentile among comparable filings
• Revenue growth: 46.1% per year; rating input score 100; 96th percentile among comparable filings
• Asset growth: 49.9% per year; rating input score 100; 96th percentile among comparable filings